These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 35707907)

  • 1. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
    Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
    Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
    Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
    Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
    Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
    Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.
    Porreca F; Navratilova E; Hirman J; van den Brink AM; Lipton RB; Dodick DW
    Cephalalgia; 2024 Mar; 44(3):3331024241238153. PubMed ID: 38477313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gepants for abortive treatment of migraine: A network meta-analysis.
    Hong P; Tan T; Liu Y; Xiao J
    Brain Behav; 2020 Aug; 10(8):e01701. PubMed ID: 32525262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ubrogepant for the treatment of migraine.
    Curto M; Capi M; Cipolla F; Cisale GY; Martelletti P; Lionetto L
    Expert Opin Pharmacother; 2020 May; 21(7):755-759. PubMed ID: 32011192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
    Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
    Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive Treatment of Migraine.
    Lipton RB
    Continuum (Minneap Minn); 2024 Apr; 30(2):364-378. PubMed ID: 38568488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs targeting calcitonin gene-related peptide for the management of migraines.
    Tana C; Cipollone F; Giamberardino MA; Martelletti P
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.